Last update Sept. 1, 2022
Very Low Risk
It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension and angina pectoris. Oral administration once daily.
It is excreted into breast milk in low (Aoki 2018, Naito 2015) or undetectable (Morgan 2018) concentration, without problems observed in infants whose mothers were on treatment with this drug. (Naito 2015, Szucs 2010, Ahn 2007)
When measured, the plasma levels of drug in these infants were undetectable. (Aoki 2018, Morgan 2018, Vasa 2013 S15-poster 29).
Because its drug elimination period is very prolonged, safer known alternatives may be preferable, especially during the neonatal period and in case of premature infant. However, the measurements, which have been undetectable, have been made in newborns, in the first week of life, and several of them were premature. (Aoki 2018)
Experts authors consider the use of this medication to be compatible during breastfeeding. (Lactmed, Hale, Ghelfi 2021, Briggs 2015)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM